CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128-Reference-Cited by-同舟云学术

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128

Published:2018-05-25 Issue:40 Volume:9 Page:26032-26045
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Badawi Mohamed¹,Kim Jihye¹,Dauki Anees¹,Sutaria Dhruvitkumar¹²,Motiwala Tasneem³,Reyes Ryan³,Wani Nissar³,Kolli Shamalatha⁴,Jiang Jinmai²,Coss Christopher C.¹⁴,Jacob Samson T.³,Phelps Mitch A.¹⁴,Schmittgen Thomas D.²

Affiliation:

1. College of Pharmacy, College of Medicine, The Ohio State University, Columbus, OH, USA

2. College of Pharmacy, University of Florida, Gainesville, FL, USA

3. Department of Molecular and Cellular Biochemistry, College of Medicine, The Ohio State University, Columbus, OH, USA

4. Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets;Cancers;2024-02-23

3. Peptide and protein delivery through cellulose, hyaluronic acid, and heparin;Peptide and Protein Drug Delivery Using Polysaccharides;2024

4. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease;Signal Transduction and Targeted Therapy;2023-10-02

5. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells;Stem Cell Research;2023-10